IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
IDEAYA Biosciences Has Selected Move-Forward Phase 2 Expansion Dose For IDE397 Monotherapy In MTAP-Deletion Squamous Non-small Cell Lung Cancer, Based On The Adverse Event Profile And Preliminary Clinical Efficacy
IDEAYA Biosciences 根據不良事件概況和初步臨床療效，爲 MTAP 缺失鱗狀非小細胞肺癌的 IDE397 單一療法選擇了向前推進的 2 期擴張劑量
- Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial responses by RECIST 1.1
- Evaluating over 40 MTAP PDX preclinical models, squamous NSCLC was identified as the most sensitive tumor type to IDE397 monotherapy where ~50% of the models observed tumor regressions at 30mg/kg QD
- Over 100,000 global annual incidence of MTAP-deletion squamous NSCLC
- 根據 AE 概況和觀察到的初步臨床療效，包括 RECIST 1.1 的多項部分反應，選擇了針對 mTAP 缺失鱗狀非小細胞肺癌的 IDE397 單一療法的 2 期擴張劑量
- 通過評估 40 多個 MTAP PDX 臨床前模型，鱗狀非小細胞肺癌被確定爲對 IDE397 單一療法最敏感的腫瘤類型，其中約 50% 的模型在 30mg/kg QD 時觀察到腫瘤回歸
- MTAP 缺失鱗狀非小細胞肺癌的全球年發病率超過 100,000
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。